Why Illumina’s new MRD kit matters for the stock

Illumina (ILMN) has drawn fresh attention after launching a whole genome based molecular residual disease research kit that targets both solid tumors and blood cancers, anchored on its NovaSeq X sequencing platform.

The solution, currently in early access and backed by initial data from partners such as Mayo Clinic, broadens Illumina’s oncology research offering at a time when the company has been working to address flat sales and weaker organic revenue growth.

The MRD launch has arrived alongside stronger share price momentum, with a 30 day share price return of 25.04% and an 18.12% year to date share price return. The 1 year total shareholder return of 88.30% contrasts with weaker 3 and 5 year total shareholder returns.

If you are watching how genomics and cancer detection tools are gaining traction, it can be useful to scan a wider set of healthcare linked AI opportunities using our 35 healthcare AI stocks

After a sharp 88.30% 1-year total shareholder return and a recent 25.04% 30-day share price gain, Illumina now trades above the average analyst price target. This raises the question of whether there is still a potential opportunity here, or if future growth is already priced in.

Most Popular Narrative: 16.6% Overvalued

Illumina closed at $158.70 compared with a most followed fair value estimate of $136.11, which is built using an 8.1% discount rate and detailed long term forecasts.

Strong and resilient growth in clinical applications especially oncology, genetic disease testing, and reproductive health continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility.

Want to see what justifies paying above the consensus fair value? The narrative leans heavily on steady revenue compounding, margin progress, and a future earnings multiple that has to hold up. Curious how those building blocks fit together across the next few years to back that $136.11 figure.

Result: Fair Value of $136.11 (OVERVALUED)

However, this hinges on clinical genomics remaining resilient and China risks easing, while tighter research budgets or faster competitor gains could still challenge that fair value story.

Another View: Cash Flows Point to a Very Different Price

While the consensus fair value sits at $136.11 and labels Illumina as 16.6% overvalued, our DCF model suggests a different perspective. On that framework, Illumina at $158.70 trades about 35.6% below an estimated future cash flow value of $246.32. Which story do you think fits the business better over time?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of optimism and concern around Illumina is clear, so do not sit on the sidelines; weigh the data for yourself with 3 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop with a single stock. Broaden your watchlist with fresh ideas from our screeners so you can spot chances others might overlook.

• Scan for potential value opportunities by reviewing companies highlighted in our 46 high quality undervalued stocks.
• Strengthen your focus on quality by checking stocks featured in the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for less followed opportunities by reviewing the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.